Insulet Corporation (NASDAQ:PODD) Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 257.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,708 shares of the medical instruments supplier's stock after acquiring an additional 61,031 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.12% of Insulet worth $22,245,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. New York Life Investment Management LLC grew its position in shares of Insulet by 79.6% in the fourth quarter. New York Life Investment Management LLC now owns 16,854 shares of the medical instruments supplier's stock valued at $4,400,000 after purchasing an additional 7,471 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in Insulet by 2.2% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 27,400 shares of the medical instruments supplier's stock worth $7,153,000 after buying an additional 600 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Insulet in the 4th quarter valued at $28,422,000. Fisher Asset Management LLC increased its stake in shares of Insulet by 7.6% in the 4th quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier's stock worth $98,605,000 after acquiring an additional 26,594 shares during the last quarter. Finally, Metis Global Partners LLC raised its holdings in shares of Insulet by 2.8% during the 4th quarter. Metis Global Partners LLC now owns 3,036 shares of the medical instruments supplier's stock worth $793,000 after acquiring an additional 83 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a report on Monday, April 28th. Barclays increased their price target on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Wall Street Zen cut Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $321.00.

Insider Activity at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president owned 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.39% of the company's stock.

Insulet Stock Up 0.3%

Shares of PODD stock traded up $0.93 during trading on Wednesday, reaching $300.92. The company's stock had a trading volume of 485,974 shares, compared to its average volume of 803,246. The company has a market capitalization of $21.18 billion, a price-to-earnings ratio of 54.12, a P/E/G ratio of 2.80 and a beta of 1.35. Insulet Corporation has a 1-year low of $173.00 and a 1-year high of $329.33. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. The stock's 50-day moving average price is $300.32 and its 200 day moving average price is $278.15.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The company's revenue was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 earnings per share. On average, research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.